Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial of Cyclosporin A in Early Adverse Risk CLL

Trial Profile

A phase II trial of Cyclosporin A in Early Adverse Risk CLL

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2019

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics
  • Acronyms CyCLLe
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Jul 2017 Status changed from recruiting to completed.
    • 29 Mar 2016 Accrual to date is 50% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top